{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:19:48Z","timestamp":1787732388311,"version":"build-2784847793"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Journal"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bj.2026.100964","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T23:31:29Z","timestamp":1772926289000},"page":"100964","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The complex interplay between hepatitis D virus and the interferon response"],"prefix":"10.1016","author":[{"given":"Claudie","family":"Eber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9022-5611","authenticated-orcid":false,"given":"Eloi R.","family":"Verrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bj.2026.100964_bib1","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/gutjnl-2018-316601","article-title":"Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis","volume":"68","author":"Chen","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.bj.2026.100964_bib2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.bj.2026.100964_bib3","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/HEP.0000000000000663","article-title":"HDV RNA and liver disease progression: What do we know?","volume":"79","author":"Stockdale","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.bj.2026.100964_bib4","unstructured":"WHO. L\u2019OMS tire la sonnette d\u2019alarme sur l\u2019h\u00e9patite virale qui tue 3 500 personnes chaque jour 2024. https:\/\/www.who.int\/fr\/news\/item\/09-04-2024-who-sounds-alarm-on-viral-hepatitis-infections-claiming-3500-lives-each-day (accessed September 26, 2025)."},{"key":"10.1016\/j.bj.2026.100964_bib5","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/gut.18.12.997","article-title":"Immunofluorescence detection of new antigen-antibody system (delta\/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers","volume":"18","author":"Rizzetto","year":"1977","journal-title":"Gut"},{"key":"10.1016\/j.bj.2026.100964_bib6","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1098\/rspb.1957.0048","article-title":"Virus interference. I. The interferon","volume":"147","author":"Isaacs","year":"1957","journal-title":"Proc R Soc Lond B Biol Sci"},{"key":"10.1016\/j.bj.2026.100964_bib7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1056\/NEJM199401133300202","article-title":"Treatment of Chronic Hepatitis D with Interferon Alfa-2a","volume":"330","author":"Farci","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bj.2026.100964_bib8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/apt.12788","article-title":"Long-term therapy of chronic delta hepatitis with peginterferon alfa","volume":"40","author":"Heller","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bj.2026.100964_bib9","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1093\/infdis\/jix656","article-title":"Interferon Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease","volume":"217","author":"Yurdaydin","year":"2018","journal-title":"The Journal of Infectious Diseases"},{"key":"10.1016\/j.bj.2026.100964_bib10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","article-title":"Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial","volume":"19","author":"Wedemeyer","year":"2019","journal-title":"The Lancet Infectious Diseases"},{"key":"10.1016\/j.bj.2026.100964_bib11","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/jvh.13366","article-title":"Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta","volume":"27","author":"Wranke","year":"2020","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.bj.2026.100964_bib12","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"eLife"},{"key":"10.1016\/j.bj.2026.100964_bib13","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","article-title":"Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes","volume":"146","author":"Ni","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bj.2026.100964_bib14","unstructured":"EMA. Hepcludex | European Medicines Agency (EMA) 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hepcludex (accessed September 26, 2025)."},{"key":"10.1016\/j.bj.2026.100964_bib15","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.3390\/cells11223531","article-title":"Treatment of Chronic Hepatitis D with Bulevirtide\u2014A Fight against Two Foes\u2014An Update","volume":"11","author":"Ferenci","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.bj.2026.100964_bib16","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.jhep.2022.06.010","article-title":"Bulevirtide with or without pegIFN\u03b1 for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies","volume":"77","author":"Lampertico","year":"2022","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.bj.2026.100964_bib17","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/gutjnl-2024-332597","article-title":"Antiviral therapy for chronic hepatitis delta: new insights from clinical trials and real-life studies","volume":"74","author":"Lampertico","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.bj.2026.100964_bib18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1056\/NEJMoa2314134","article-title":"Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D","volume":"391","author":"Asselah","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bj.2026.100964_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(24)02207-4","article-title":"WED-395 Undetectable hepatitis delta virus RNA at the end of treatment with bulevirtide and pegylated interferon alpha-2a is an important predictor of 48 weeks sustained virologic response in chronic hepatitis delta","volume":"80","author":"Zoulim","year":"2024","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.bj.2026.100964_bib20","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2023.05.001","article-title":"EASL Clinical Practice Guidelines on hepatitis delta virus","volume":"79","author":"Brunetto","year":"2023","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.bj.2026.100964_bib21","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/hep.32259","article-title":"A phase 2 dose\u2010finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis","volume":"75","author":"Yurdaydin","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.bj.2026.100964_bib22","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0168-8278(22)00437-8","article-title":"GS010 - Efficacy and safety of finite 48-week treatment with the siRNA JNJ-3989 and the capsid assembly modulator (CAM-N) JNJ-6379 in HBeAg negative virologically suppressed (VS) chronic hepatitis B (CHB) patients: results from REEF-2 study","volume":"77","author":"Agarwal","year":"2022","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.bj.2026.100964_bib23","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S2468-1253(23)00148-6","volume":"8","author":"Yuen","year":"2023","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"10.1016\/j.bj.2026.100964_bib24","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S0168-8278(24)00475-6","article-title":"OS-034 Safety and efficacy of REP 2139-Mg in hepatitis D patients with advanced liver disease: an international compassionate use program","volume":"80","author":"Stern","year":"2024","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.bj.2026.100964_bib25","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/S0168-8278(24)00569-5","article-title":"LBP-001 Rapid reductions of HDV RNA and ALT with the monoclonal antibody, BJT-778: results from a phase 2 study","volume":"80","author":"Agarwal","year":"2024","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.bj.2026.100964_bib26","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/S0168-8278(24)00565-8","volume":"80","author":"Asselah","year":"2024","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.bj.2026.100964_bib27","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1097\/HEP.0000000000000309","article-title":"Treatment of chronic hepatitis D with peginterferon lambda\u2014the phase 2 LIMT-1 clinical trial","volume":"77","author":"Etzion","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.bj.2026.100964_bib28","unstructured":"Inc EB. Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta n.d. https:\/\/www.prnewswire.com\/news-releases\/eiger-to-discontinue-phase-3-limt-2-trial-of-peginterferon-lambda-in-patients-with-chronic-hepatitis-delta-301925362.html (accessed December 12, 2024)."},{"key":"10.1016\/j.bj.2026.100964_bib29","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1038\/s41598-017-03946-9","article-title":"Both interferon alpha and lambda can reduce all intrahepatic HDV infection markers in HBV\/HDV infected humanized mice","volume":"7","author":"Giersch","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.bj.2026.100964_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2024.199451","article-title":"Interferon alpha induces a stronger antiviral effect than interferon lambda in HBV\/HDV infected humanized mice","volume":"349","author":"Duehren","year":"2024","journal-title":"Virus Research"},{"key":"10.1016\/j.bj.2026.100964_bib31","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.3390\/v13081532","article-title":"Cell Culture Models for the Study of Hepatitis D Virus Entry and Infection","volume":"13","author":"Heuschkel","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.bj.2026.100964_bib32","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3390\/v16050716","article-title":"Cell Culture Models for Hepatitis B and D Viruses Infection: Old Challenges, New Developments and Future Strategies","volume":"16","author":"Carpentier","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.bj.2026.100964_bib33","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.jhep.2023.01.005","article-title":"Hepatitis D virus interferes with hepatitis B virus RNA production via interferon-dependent and -independent mechanisms","volume":"78","author":"Lucifora","year":"2023","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.bj.2026.100964_bib34","first-page":"3858","article-title":"Growth of human hepatoma cells lines with differentiated functions in chemically defined medium","volume":"42","author":"Nakabayashi","year":"1982","journal-title":"Cancer Res"},{"key":"10.1016\/j.bj.2026.100964_bib35","doi-asserted-by":"crossref","first-page":"13001","DOI":"10.1128\/JVI.76.24.13001-13014.2002","article-title":"Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication","volume":"76","author":"Blight","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.bj.2026.100964_bib36","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.3390\/cells11152298","article-title":"Transcriptional and Epigenetic Consequences of DMSO Treatment on HepaRG Cells","volume":"11","author":"Dubois-Pot-Schneider","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.bj.2026.100964_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104812","article-title":"Current knowledge on Hepatitis Delta Virus replication","volume":"179","author":"Lucifora","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bj.2026.100964_bib38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/hep.28013","article-title":"A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses","volume":"63","author":"Verrier","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.bj.2026.100964_bib39","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1017\/S1355838202026432","article-title":"Hepatitis delta virus ribonucleoproteins shuttle between the nucleus and the cytoplasm","volume":"8","author":"Tavanez","year":"2002","journal-title":"RNA"},{"key":"10.1016\/j.bj.2026.100964_bib40","first-page":"25","article-title":"HDV RNA replication: ancient relic or primer?","volume":"307","author":"Macnaughton","year":"2006","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.bj.2026.100964_bib41","article-title":"Microbial sensing by Toll-like receptors and intracellular nucleic acid sensors","volume":"7","author":"Pandey","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.bj.2026.100964_bib42","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.molcel.2014.07.003","article-title":"The innate immune sensor LGP2 activates antiviral signaling by regulating MDA5-RNA interaction and filament assembly","volume":"55","author":"Bruns","year":"2014","journal-title":"Mol Cell"},{"key":"10.1016\/j.bj.2026.100964_bib43","doi-asserted-by":"crossref","first-page":"11664","DOI":"10.1093\/nar\/gkaa935","article-title":"Viral RNA recognition by LGP2 and MDA5, and activation of signaling through step-by-step conformational changes","volume":"48","author":"Duic","year":"2020","journal-title":"Nucleic Acids Research"},{"key":"10.1016\/j.bj.2026.100964_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aar3993","article-title":"LGP2 binds to PACT to regulate RIG-I\u2013 and MDA5-mediated antiviral responses","volume":"12","author":"Sanchez David","year":"2019","journal-title":"Sci Signal"},{"key":"10.1016\/j.bj.2026.100964_bib45","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jhep.2017.05.010","article-title":"A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-\u03b2 induction","volume":"67","author":"Su\u00e1rez-Amar\u00e1n","year":"2017","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.bj.2026.100964_bib46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2018.02.021","article-title":"Hepatitis D virus replication is sensed by MDA5 and induces IFN-\u03b2\/\u03bb responses in hepatocytes","volume":"69","author":"Zhang","year":"2018","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.bj.2026.100964_bib47","article-title":"Effect of variants in LGP2 on MDA5-mediated activation of interferon response and suppression of hepatitis D virus replication","author":"Gillich","year":"2022","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.bj.2026.100964_bib48","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1038\/s41467-018-05745-w","article-title":"Nuclear-resident RIG-I senses viral replication inducing antiviral immunity","volume":"9","author":"Liu","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.bj.2026.100964_bib49","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jhep.2020.11.032","article-title":"New insights into HDV persistence: The role of interferon response and implications for upcoming novel therapies","volume":"74","author":"Zhang","year":"2021","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.bj.2026.100964_bib50","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bj.2026.100964_bib51","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41392-025-02264-1","article-title":"Pattern recognition receptors: function, regulation and therapeutic potential","volume":"10","author":"Chen","year":"2025","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.bj.2026.100964_bib52","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nature03464","article-title":"IRF-7 is the master regulator of type-I interferon-dependent immune responses","volume":"434","author":"Honda","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bj.2026.100964_bib53","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jhep.2023.10.030","article-title":"JAK1 promotes HDV replication and is a potential target for antiviral therapy","volume":"80","author":"Heuschkel","year":"2024","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.bj.2026.100964_bib54","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00703-25","article-title":"Reconstitution of interferon regulatory factor 7 expression restores interferon beta induction in Huh7 cells","volume":"99","author":"Betz","year":"2025","journal-title":"J Virol"},{"key":"10.1016\/j.bj.2026.100964_bib55","doi-asserted-by":"crossref","first-page":"16739","DOI":"10.1074\/jbc.M414139200","article-title":"Distinct Poly(I-C) and Virus-activated Signaling Pathways Leading to Interferon-\u03b2 Production in Hepatocytes","volume":"280","author":"Li","year":"2005","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.bj.2026.100964_bib56","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.virol.2006.03.022","article-title":"Sendai virus defective-interfering genomes and the activation of interferon-beta","volume":"351","author":"Strahle","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.bj.2026.100964_bib57","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1073\/pnas.0401771101","article-title":"Genomic analysis of the host response to hepatitis B virus infection","volume":"101","author":"Wieland","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bj.2026.100964_bib58","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0092-8674(94)90154-6","article-title":"The human interferon \u03b1\u03b2 receptor: Characterization and molecular cloning","volume":"77","author":"Novick","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.bj.2026.100964_bib59","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000078","article-title":"Farnesoid X receptor alpha ligands inhibit HDV in vitro replication and virion infectivity","volume":"7","author":"Legrand","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.bj.2026.100964_bib60","article-title":"A novel in vitro system for simultaneous infections with hepatitis B, C, D and E viruses","volume":"7","author":"Fouill\u00e9","year":"2025","journal-title":"JHEP Reports Innovation in Hepatology"},{"key":"10.1016\/j.bj.2026.100964_bib61","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01280-25","article-title":"Multimodal characterization of the responsiveness of eight hepatitis D virus genotype isolates to interferon-alpha treatment","volume":"99","author":"Ding","year":"2025","journal-title":"J Virol"},{"key":"10.1016\/j.bj.2026.100964_bib62","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nsmb.1440","article-title":"Capped small RNAs and MOV10 in human hepatitis delta virus replication","volume":"15","author":"Haussecker","year":"2008","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.bj.2026.100964_bib63","doi-asserted-by":"crossref","first-page":"15118","DOI":"10.1073\/pnas.232416799","article-title":"Replicating hepatitis delta virus RNA is edited in the nucleus by the small form of ADAR1","volume":"99","author":"Wong","year":"2002","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.bj.2026.100964_bib64","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1365-2893.2005.00663.x","article-title":"The large form of ADAR 1 is responsible for enhanced hepatitis delta virus RNA editing in interferon-alpha-stimulated host cells","volume":"13","author":"Hartwig","year":"2006","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.bj.2026.100964_bib65","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jhep.2022.05.023","article-title":"Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread","volume":"77","author":"Zhang","year":"2022","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.bj.2026.100964_bib66","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/hep.22654","article-title":"Hepatitis delta virus inhibits alpha interferon signaling","volume":"49","author":"Pugnale","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.bj.2026.100964_bib67","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.162404","article-title":"Persistent hepatic IFN system activation in HBV-HDV infection determines viral replication dynamics and therapeutic response","volume":"8","author":"Chida","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.bj.2026.100964_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022200","article-title":"USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon \u03b1 response","volume":"6","author":"Fran\u00e7ois-Newton","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bj.2026.100964_bib69","doi-asserted-by":"crossref","first-page":"7034","DOI":"10.1073\/pnas.0707882105","article-title":"Interferon signaling and treatment outcome in chronic hepatitis C","volume":"105","author":"Sarasin-Filipowicz","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bj.2026.100964_bib70","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/hep.29574","article-title":"Genetic diversity and worldwide distribution of the deltavirus genus: A study of 2,152 clinical strains","volume":"66","author":"Le Gal","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.bj.2026.100964_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2025.106514","article-title":"Clinical trials for Hepatitis Delta Virus in the WHO African region: A neglected virus among neglected viruses","volume":"91","author":"Delphin","year":"2025","journal-title":"Journal of Infection"},{"key":"10.1016\/j.bj.2026.100964_bib72","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jhep.2019.12.028","article-title":"Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1","volume":"72","author":"Spaan","year":"2020","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.bj.2026.100964_bib73","article-title":"Strain-specific responsiveness of hepatitis D virus to interferon-alpha treatment","volume":"5","author":"Giersch","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.bj.2026.100964_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(25)01987-7","article-title":"FRI-254-YI Early immune responses define Peg-IFN\u03b1-mediated treatment outcome in chronic hepatitis D virus infection","volume":"82","author":"Anim","year":"2025","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.bj.2026.100964_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2020.100098","article-title":"TNF-alpha inhibition ameliorates HDV-induced liver damage in a mouse model of acute severe infection","volume":"2","author":"Usai","year":"2020","journal-title":"JHEP Reports"},{"key":"10.1016\/j.bj.2026.100964_bib76","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1089\/hum.2024.040","article-title":"Innate Immune Sensing of Adeno-Associated Virus Vectors","volume":"35","author":"Cao","year":"2024","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.bj.2026.100964_bib77","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1128\/JVI.74.9.4165-4173.2000","article-title":"Intrahepatic Induction of Alpha\/Beta Interferon Eliminates Viral RNA-Containing Capsids in Hepatitis B Virus Transgenic Mice","volume":"74","author":"Wieland","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.bj.2026.100964_bib78","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hep.31695","article-title":"Therapeutic Potential of TLR8 Agonist GS\u20109688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators","volume":"74","author":"Amin","year":"2021","journal-title":"Hepatology"}],"container-title":["Biomedical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S231941702600020X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S231941702600020X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:33:24Z","timestamp":1787729604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S231941702600020X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":78,"alternative-id":["S231941702600020X"],"URL":"https:\/\/doi.org\/10.1016\/j.bj.2026.100964","relation":{},"ISSN":["2319-4170"],"issn-type":[{"value":"2319-4170","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The complex interplay between hepatitis D virus and the interferon response","name":"articletitle","label":"Article Title"},{"value":"Biomedical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bj.2026.100964","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Chang Gung University.","name":"copyright","label":"Copyright"}],"article-number":"100964"}}